Why the study?
Despite therapeutic options, high mortality in pulmonary arterial hypertension remains a challenge due to complex pathophysiology, prompting review of the nitric oxide pathway and potential novel therapies.
Understanding the nitric oxide pathway and its interactions with other pathways is essential for developing new therapies to improve clinical outcomes in pulmonary arterial hypertension.
May support NO pathway exploration in PAH; leaves open clinical efficacy pending randomized trials.
Pulmonary arterial hypertension (PAH) is a severe disease with a resultant increase of the mean pulmonary arterial pressure, right ventricular hypertrophy and eventual death. Research in recent years has produced various therapeutic options for its clinical management but the high mortality even under treatment remains a big challenge attributed to the complex pathophysiology. Studies from clinical and non-clinical experiments have revealed that the nitric oxide (NO) pathway is one of the key pathways underlying the pathophysiology of PAH. Many of the essential drugs used in the management of PAH act on this pathway highlighting its significant role in PAH. Meanwhile, several novel compounds targeting on NO pathway exhibits great potential to become future therapy medications. Furthermore, the NO pathway is found to interact with other crucial pathways. Understanding such interactions could be helpful in the discovery of new drug that provide better clinical outcomes.
No takes yet. Share an insight, caveat, or question.
Tettey et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: